相关实验视频

Updated: Sep 16, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

三阴性乳腺癌的化学免疫调节:最大限度地提高抗PD-1化学免疫治疗疗效的关键

Mohammed O Gbadamosi^1,2,3, Elizabeth Molchan¹, Mariana S Makarem¹

¹Department of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USA.

|July 9, 2025

概括

用抗PD-1化疗免疫疗法 (CIT) 治疗三阴性乳腺癌 (TNBC) 的结果各不相同. 了解化疗如何影响免疫系统是提高TNBC患者CIT疗效的关键.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

三阴性乳腺癌 (TNBC) 是一种具有攻击性的乳腺癌亚型,治疗选择有限,结果差.
抗PD-1化疗免疫疗法 (CIT) 结合化疗与PD-1阻断来增强抗瘤免疫力.
在晚期TNBC中,CIT的临床益处通常是有限的和不一致的.

研究的目的:

审查TNBC中使用的第一线化疗剂的免疫调节特性.
探索如何优化化疗免疫调节可以提高TNBC中CIT疗效.
突出了解患者对化疗诱导免疫调节的特定反应的需要.

主要方法:

对TNBC,化疗和免疫治疗研究的文献综述.
在TNBC中分析常见化疗剂的免疫调节机制.
讨论个性化化疗免疫调节的策略.

主要成果:

化疗剂具有多种免疫调节作用,可以影响抗PD-1疗法.
个别患者对化疗免疫效应的反应有很大差异.
缺乏对这些个体差异的理解有助于产生异质的CIT结果.

结论:

优化化疗免疫调节具有显著的潜力,可以提高TNBC的CIT疗效.
对化疗的患者特异性免疫调节作用的进一步研究对于TNBC治疗的进步至关重要.
对CIT的个性化方法可以克服当前治疗高级TNBC的局限性.

关键词:

化学免疫调节化学免疫调节化疗化疗是一种化学疗法.免疫检查点抑制剂免疫检查点抑制剂免疫疗法免疫疗法三重阴性乳腺癌是什么

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...